PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX
(Financial Post, 2025-12-24T13:34:38Z)